PE20010898A1 - Inhibidores de la formacion del cd23 - Google Patents

Inhibidores de la formacion del cd23

Info

Publication number
PE20010898A1
PE20010898A1 PE2000001156A PE0011562000A PE20010898A1 PE 20010898 A1 PE20010898 A1 PE 20010898A1 PE 2000001156 A PE2000001156 A PE 2000001156A PE 0011562000 A PE0011562000 A PE 0011562000A PE 20010898 A1 PE20010898 A1 PE 20010898A1
Authority
PE
Peru
Prior art keywords
compound
refers
compounds
formation
inhibitors
Prior art date
Application number
PE2000001156A
Other languages
English (en)
Inventor
Andrew Faller
John Gerard Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE20010898A1 publication Critical patent/PE20010898A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE R ES ISOPROPILO; n ES 0; R1 ES NAFTILMETILO; R2 ES T-BUTILO; R3 ES METILO; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DEL COMPUESTO I QUE COMPRENDE DESPROTEGER UN COMPUESTO II; X ES BENCILO, TRIMETILSILILO; b)HACER REACCIONAR UN COMPUESTO III, GRUPO HIDROXI OPCIONALMENTE PROTEGIDO CON HIDROXILAMINA; TAMBIEN SE REFIERE A LOS COMPUESTOS INTERMEDIOS. EL COMPUESTO I ES UN INHIBIDOR DE LA FORMACION DE CD23 SOLUBLE (RECEPTOR FceRII DE BAJA AFINIDAD DE LA IgE, BLASTO 2) Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ALERGIA, TRASTORNOS INFLAMATORIOS, ENFERMEDADES AUTOINMUNES
PE2000001156A 1999-10-27 2000-10-27 Inhibidores de la formacion del cd23 PE20010898A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925470.8A GB9925470D0 (en) 1999-10-27 1999-10-27 Novel compounds

Publications (1)

Publication Number Publication Date
PE20010898A1 true PE20010898A1 (es) 2001-10-13

Family

ID=10863507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001156A PE20010898A1 (es) 1999-10-27 2000-10-27 Inhibidores de la formacion del cd23

Country Status (32)

Country Link
US (2) US6673965B1 (es)
EP (1) EP1224164B1 (es)
JP (1) JP3922431B2 (es)
KR (1) KR20020044578A (es)
CN (1) CN1182107C (es)
AR (1) AR026244A1 (es)
AT (1) ATE284382T1 (es)
AU (1) AU766072B2 (es)
BR (1) BR0015082A (es)
CA (1) CA2389319A1 (es)
CO (1) CO5261576A1 (es)
CZ (1) CZ20021424A3 (es)
DE (1) DE60016622T2 (es)
DK (1) DK1224164T3 (es)
ES (1) ES2233474T3 (es)
GB (1) GB9925470D0 (es)
GC (1) GC0000142A (es)
HK (1) HK1049146A1 (es)
HU (1) HUP0203270A3 (es)
IL (1) IL149364A0 (es)
MX (1) MXPA02004228A (es)
MY (1) MY133601A (es)
NO (1) NO20021965L (es)
NZ (1) NZ518566A (es)
PE (1) PE20010898A1 (es)
PL (1) PL356524A1 (es)
PT (1) PT1224164E (es)
SI (1) SI1224164T1 (es)
TW (1) TW561141B (es)
UY (1) UY26416A1 (es)
WO (1) WO2001030747A1 (es)
ZA (1) ZA200203255B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334636A2 (en) * 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
US8945575B2 (en) 2009-12-01 2015-02-03 Trustees Of Boston University Treatment of IgE-mediated disease
WO2011073845A1 (en) 2009-12-16 2011-06-23 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
CN104529883A (zh) 2011-03-07 2015-04-22 辉瑞大药厂 可用作抗菌剂的氟吡啶酮衍生物
AU2012238374B2 (en) 2011-04-08 2015-04-02 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
CN103492368A (zh) 2011-04-08 2014-01-01 辉瑞大药厂 用作抗菌剂的咪唑、吡唑和噻唑衍生物
EP2525213A1 (en) * 2011-05-16 2012-11-21 Renishaw plc Spectroscopic apparatus and methods for determining components present in a sample

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
GB9813451D0 (en) * 1998-06-22 1998-08-19 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
US6673965B1 (en) 2004-01-06
SI1224164T1 (en) 2005-06-30
NO20021965L (no) 2002-06-13
HUP0203270A2 (hu) 2003-02-28
DE60016622D1 (de) 2005-01-13
NO20021965D0 (no) 2002-04-25
AR026244A1 (es) 2003-02-05
WO2001030747A1 (en) 2001-05-03
DK1224164T3 (da) 2005-03-29
CO5261576A1 (es) 2003-03-31
BR0015082A (pt) 2003-04-15
IL149364A0 (en) 2002-11-10
AU1389501A (en) 2001-05-08
JP2003512450A (ja) 2003-04-02
US20040077727A1 (en) 2004-04-22
UY26416A1 (es) 2001-05-31
PT1224164E (pt) 2005-04-29
CN1182107C (zh) 2004-12-29
AU766072B2 (en) 2003-10-09
CN1411436A (zh) 2003-04-16
KR20020044578A (ko) 2002-06-15
ES2233474T3 (es) 2005-06-16
MY133601A (en) 2007-11-30
EP1224164A1 (en) 2002-07-24
HUP0203270A3 (en) 2003-11-28
NZ518566A (en) 2004-02-27
PL356524A1 (en) 2004-06-28
JP3922431B2 (ja) 2007-05-30
EP1224164B1 (en) 2004-12-08
ZA200203255B (en) 2003-03-20
CA2389319A1 (en) 2001-05-03
ATE284382T1 (de) 2004-12-15
CZ20021424A3 (cs) 2002-09-11
DE60016622T2 (de) 2005-11-03
HK1049146A1 (en) 2003-05-02
TW561141B (en) 2003-11-11
GC0000142A (en) 2005-06-29
MXPA02004228A (es) 2002-10-17
GB9925470D0 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
GT200100196A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
EA200300306A1 (ru) Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
PE20000412A1 (es) Derivados biciclicos del acido hidroxamico
ME00768B (me) Derivati supstituisanih benzol sulfonamida kao pro-lekovi cox-2 inhibitora
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
ATE280763T1 (de) Matrix-metalloproteinase-hemmer
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
NO20004091D0 (no) Bicykliske pyrrolderivater som MCP-1 inhibitorer
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
RS50574B (sr) (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline
EA200600348A1 (ru) Новые соединения
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
EA199800923A1 (ru) Новые 2,3-двузамещенные 4(3н)-хиназолины
CO5570674A2 (es) Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos
DK1104759T3 (da) Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
PT1337535E (pt) Derivados de benzodiazepina
SV2002000244A (es) Metodos y compuestos para inhibir mrp1 ref.x-13353
PE20010898A1 (es) Inhibidores de la formacion del cd23
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
BR0114156A (pt) Forma amorfa de inibidor de ciclo de célula

Legal Events

Date Code Title Description
FA Abandonment or withdrawal